cas 394-04-7|| where to buy 5-Fluoro-2-methoxybenzoic acid

Nom du produit:5-Fluoro-2-methoxybenzoic acid

IUPAC Name:5-fluoro-2-methoxybenzoic acid

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM160577-1000g	in stock	ǤŢǊȎ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 394-04-7 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:394-04-7; Formule moléculaire:C8H7FO3; Point de fusion:-; Code SMILES:O=C(O)C1=CC(F)=CC=C1OC; Densité:

: Numéro de catalogue:CM160577; Poids moléculaire:170.14; Point d'ébullition:294°C at 760 mmHg; N° Mdl:MFCD00671765; Stockage:Store at room temperature.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Revumenib; Syndax announced pivotal AUGMENT-101 trial of Revumenib in relapsed/refractory KMT2Ar acute leukemia met primary endpoint and stopped early for efficacy following protocol-defined interim analysis. Revumenib is a potent, selective, small molecule inhibitor of the menin-KMT2A binding interaction that is being developed for the treatment of KMT2A-rearranged, also known as mixed lineage leukemia rearranged or MLLr, acute leukemias including ALL and AML, and NPM1-mutant AML.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

: Pirtobrutinib; Eli Lilly and Company announced that the U.S. FDA approved Jaypirca® (Pirtobrutinib) for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor and a BCL-2 inhibitor. Jaypirca (Pirtobrutinib) is a highly selective (300 times more selective for BTK versus 98% of other kinases tested in preclinical studies), non-covalent (reversible) inhibitor of the enzyme BTK.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.